INFORMED CONSENT FORM

Study Title: Evaluation of the Efficacy of Oral Hydration Method Compared to Intravenous Hydration in Preventing Contrast-Associated Acute Kidney Injury in the Emergency Department

Principal Investigator: Assoc. Prof. Mustafa Çalık

Co-Investigators: Dr. Alper Görkem Çimen, Dr. Yunus Emre Gemici, Dr. Furkan Ay

Study Location: Gaziosmanpaşa Training and Research Hospital, Emergency Medicine Clinic

Document Date: November 7, 2025

---

1. INFORMATION ABOUT THE STUDY

You are being invited to participate in a research study titled "Evaluation of the Efficacy of Oral Hydration Method Compared to Intravenous Hydration in Preventing Contrast-Associated Acute Kidney Injury in the Emergency Department". You have been selected because you have been identified as having a high risk of developing contrast nephropathy. Participation is entirely voluntary.

Purpose of the Study: The purpose is to develop treatment methods to prevent kidney damage (CA-AKI) in patients with elevated kidney function values who undergo contrast-enhanced CT scans in the emergency department (ED). Contrast media can be nephrotoxic, and the proven preventive treatment is hydration. This study compares two different fluid administration routes (oral vs. intravenous). A total of 198 participants will be enrolled in this single-center study.

What to Expect During the Study: Patients will be randomly assigned to one of two groups:

- **Oral Hydration Group:** Participants will drink 500 mL of water 1 hour before the contrast media administration and 125 mL/hour for 4 hours (total 500 mL) after the procedure under nursing supervision.
- **Intravenous (IV) Hydration Group:** Participants will receive isotonic 0.9% NaCl solution intravenously before and after the procedure at a rate determined by their body weight, consistent with current medical guidelines.
- **Follow-up:** If discharged, you will be asked to return to the hospital 48–72 hours later for a follow-up blood test to evaluate your kidney functions. Approximately 4 mL of blood will be drawn twice (at initial admission and at follow-up).

2. RISKS, BENEFITS, AND VOLUNTARY PARTICIPATION

- **Risks:** The treatments used are standard, proven methods. In patients with advanced heart failure, fluid therapy can stress the heart. Therefore, patients with active heart failure symptoms are excluded, and those with asymptomatic heart failure will receive half-doses.
- **Benefits:** By participating, you contribute to the scientific development of effective emergency treatments for patients at risk of kidney damage.
- **Withdrawal:** You are free to withdraw from the study at any time without any penalty or loss of medical care.
- **Confidentiality:** Your personal identity will be kept confidential. Only authorized ethical committees or official authorities may review your data if necessary.

3. COST AND CONTACT INFORMATION

- **Cost:** Participation is free of charge, and no payment will be made to participants.

- **Contact:** For any questions or in case of a health issue related to the study, you may contact:
    - Dr. Alper Görkem Çimen (Emergency Medicine Resident)
    - **Phone:** 0535 305 47 20

4. PARTICIPANT DECLARATION

I have read the information above and it has been explained to me by Dr. _____. I understand that my participation is voluntary and that I can withdraw at any time. I understand that my personal data will be kept confidential and that I will not incur any costs for participating. I consent to participate in this clinical research under these conditions.

Participant's Signature: _____Date: _____

Investigator's Signature: _____Date: _____